Navigation Links
Metastatic pancreatic, primary breast cancer have common growth mechanisms, study suggests
Date:7/11/2013

rmal and cancerous cells, so targeting integrins for stopping the growth of cancer is not a promising strategy. What is unique about asTF is that it binds to integrins on vessel-forming cells, activating them. We've shown that certain cancer cells share those same qualities, so if you target asTFwhich is elevated in cancerthere is significant potential to spare the 'good' parts of the cellular system while removing the 'bad' cancer-specific protein from the game," explains Bogdanov.

"Many routine therapies such as chemotherapy or radiation may not always be efficient. Targeting asTF in tumors using our monoclonal antibody may form a potent additional anticancer strategy in combination with conventional avenues", says Versteeg.


'/>"/>

Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati Academic Health Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Mechanism found connecting metastatic breast cancer and arthritis
2. Cancerous tumors deliver pro-metastatic information in secreted vesicles
3. Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma?
4. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
5. Thomas Jefferson University researchers discover new pathways that drive metastatic prostate cancer
6. LSUHSC research discovers new drug target for metastatic breast cancer
7. Modulating the immune system to combat metastatic cancer
8. How cancer spreads: Metastatic tumor a hybrid of cancer cell and white blood cell
9. PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
10. Commonly used diabetes drug may help to prevent primary liver cancer
11. Biology professor secures grant to save West Virginias primary natural history collection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... Genomic research could help doctors better target a drug widely ... by Genomic Health Inc. (Nasdaq: GHDX) and the Translational Genomics ... in colon cancer. It is used in early disease, following ... is also used in advanced disease to slow progression of ...
... were initiated in 1971 and have become a leading ... enzyme technology and biocatalysis, putting an emphasis on emerging ... aspects. The proposed scope and thrust of the ... on new developments in fields including protein design and ...
... report that they are the first to show in molecular ... split up via gene duplication to pursue their ... Proceedings of the National Academy of Sciences , validates a ... also confirms the ancestry of a family of "antifreeze proteins" ...
Cached Biology News:TGen and Genomic Health Inc. discover genes affecting cancer drug 2Researchers show how 1 gene becomes 2 (with different functions) 2Researchers show how 1 gene becomes 2 (with different functions) 3
(Date:7/28/2015)... YORK , July 28, 2015 Tauriga ... a diversified life sciences company, today announced that its ... shares of common stock of the Company from 1,000,000,000 ... on July 27, 2015 at the Law Offices of ...  At the Special Meeting, there were 480,655,929 shares of ...
(Date:7/28/2015)... 28, 2015  Moerae Matrix Inc. announced today ... trial with MMI-0100, a first-in-class inhibitor of MAPKAP ... pulmonary disorders characterized by inflammation and fibrosis.  The ... , is a double-blind, two-way cross-over design ... and tolerability of MMI-0100 when given via inhalation ...
(Date:7/28/2015)... OF PRUSSIA, Pa. , July 28, 2015 /PRNewswire/ ... U.S. Food and Drug Administration has accepted for review ... investigational recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment ... met all primary endpoints. Hemophilia ... deficient or defective factor VIII; nearly all affected patients ...
(Date:7/28/2015)... RESEARCH TRIANGLE PARK, N.C., July 28, 2015  United ... its financial results for the second quarter ended ... nearly 300% as compared to the second quarter ... said Roger Jeffs, Ph.D., United Therapeutics, President and ... was due to an increase in the number ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... , ATLANTA, Oct. 6 CryoLife, Inc., ... and cardiovascular tissue processing company, today announced that it has ... and Drug Administration (FDA) for its CryoValve® SG aortic human ... in obtaining a Humanitarian Device Exemption (HDE) for the CryoValve ...
... , ROCKVILLE, Md., Oct. 6 Novavax, Inc. (Nasdaq: ... Rahul Singhvi, President and CEO of Novavax, will be making ... October 7th, 2009 at the Palais des Congres de Lyon, ... ,Innovative Approaches to RSV vaccine development and VLP based vaccines, ...
... Oct. 6 State, county and local government leaders ... REGN ) and BioMed Realty Trust, Inc. (NYSE: ... new 229,000 square foot corporate headquarters and research facility ... New York. Featured speakers at the ceremony were Leonard ...
Cached Biology Technology:CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 2CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 3CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 4Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview 2Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview 3Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview 4Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview 5
... 1 outflow Single-cell and patch delivery ... solution change Very small dead volume , ... 360, 250 and 100 micron delivery tips ... micromanipulator Available in 4, 8, and 16 ...
... Racks are ideal for storage and transport ... polypropylene racks withstand extreme temperatures, making them ... may also be autoclaved for use in ... side accommodates 0.5ml microcentrifuge tubes, the other ...
... consists of universal lysis buffer, PCR mix, ... 100 25 l volume PCR reactions. This ... negative or positive rod and coccus bacteria, ... Cereus, Staphylococcus Aureus, Streptococcus Agalactiae, and etc. ...
... BacVector Insect Cell Medium is optimized for ... Insect Cells. In this protein-free medium, Sf9 ... * 107 cells/ml with viabilities above 95%. ... assays, where color from X-gluc staining of ...
Biology Products: